진행성 유방암의 맞춤 항암요법의 최신 지견

키워드

참고문헌 (41)

1. Wilkins EW, Jr., "Pulmonary resection for metastatic neoplasms in the lung. Experience at the Massachusetts General Hospital", Am J Surg, 135, pp.480~483 (1978)
2. Simmons C, "Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?", Ann Oncol (2009)
3. Beatson G, "On the treatment of inoperable carcinoma of the mamma:suggestions for a new method of treatment with illustrative cases", Lancet, 2, pp.104~ (1896)
4. Bloom ND, "The role of progesterone receptors in the management of advanced breast cancer", Cancer, 45, pp.2992~2997 (1980)
5. Osborne CK, "The value of estrogen and progesterone receptors in the treatment of breast cancer", Cancer, 46, pp.2884~2888 (1980)
6. Buzdar AU, "Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group", Cancer, 83, pp.1142~1152 (1998)
7. Dombernowsky P, "Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate", J Clin Oncol, 16, pp.453~461 (1998)
8. Gershanovich M, "Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR", BC3), 1998, pp.9, 639~645
9. Mauri D, "Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis", J Natl Cancer Inst, 98, pp.1285~1291 (2006)
10. Fisher B, "Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study", J Natl Cancer Inst, 97, pp.1652~1662 (2005)
11. Mouridsen HT, "Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women", Curr Med Res Opin, 22, pp.1609~1621 (2006)
12. Lenihan DJ, "Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer", Oncologist, 13, pp.1224~1234 (2008)
13. Howell A, "Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials", Cancer, 104, pp.236~239 (2005)
14. Howell A, "Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial", J Clin Oncol, 22, pp.1605~1613 (2004)
15. Taylor CW, "Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study", J Clin Oncol, 16, pp.994~999 (1998)
16. Klijn JG, "Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials", J Clin Oncol, 19, pp.343~353 (2001)
17. Liu Y, "MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo", Breast Cancer Res Treat, 34, pp.97~117 (1995)
18. De Laurentiis M, "A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer", Clin Cancer Res, 11, pp.4741~4748 (2005)
19. Harris L, "American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer", J Clin Oncol, 25, pp.5287~5312 (2007)
20. Smith CL, "Coactivator and corepressor regulation of the agonist", antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen, 1997, pp.11, 657~666
21. Lim HS, "Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer", J Clin Oncol, 25, pp.3837~3845 (2007)
22. Ross JS, "The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine", Oncologist, 14, pp.320~368 (2009)
23. Wolff AC, "American Society of Clinical Oncology", College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, 2007, pp.25, 118~145
24. Meng S, "HER-2 gene amplification can be acquired as breast cancer progresses", Proc Natl Acad Sci U S A, 101, pp.9393~9398
25. Guarneri V, "Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management", Oncologist, 13, pp.838~844 (2008)
26. Cobleigh MA, "Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease", J Clin Oncol, 17, pp.2639~2648 (1999)
27. Vogel CL, "Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer", J Clin Oncol, 20, pp.719~726 (2002)
28. Dybdal N, "Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab", Breast Cancer Res Treat, 93, pp.3~11 (2005)
29. de Alava E, "Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer", J Clin Oncol, 25, pp.2656~2663 (2007)
30. Seidman AD, "Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840", J Clin Oncol, 26, pp.1642~1649 (2008)
31. Slamon DJ, "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2", N Engl J Med, 344, pp.783~792 (2001)
32. von Minckwitz G, "Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26", breast international group 03-05 study, 2009, pp.27, 1999~2006
33. Burstein HJ, "A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer", Ann Oncol, 19, pp.1068~1074 (2008)
34. Johnston S, "Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy", J Clin Oncol, 26, pp.1066~1072 (2008)
35. Crown JP, "Pooled analysis of diarrhea events in patients with cancer treated with lapatinib", Breast Cancer Res Treat, 112, pp.317~325 (2008)
36. Moy B, "Lapatinib-associated toxicity and practical management recommendations", Oncologist, 12, pp.756~765 (2007)
37. Lin N, "EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT)", Journal of Clinical Oncology, 25, pp.1012~ (2007)
38. O’Shaughnessy J, "A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy", J Clin Oncol, 26, pp.1015~ (2008)
39. Miller K, "Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer", N Engl J Med, 357, pp.2666~2676 (2007)
40. Miles D, "Randomised, double-blind, placebo-controlled phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cnacer: AVADO", J Clin Oncol, 26, pp.1008s~ (2008)
41. Sorlie T, "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", Proc Natl Acad Sci U S A, 98, pp.10869~10874 (2001)

관련 논문AI추천